Background: The poor clinical prognosis of Stage IIIB colon cancer patients is due in part to the current lack of an effective diagnostic method being available and highlights a need for the identification of novel biomarkers like microRNA (miRNA).
Introduction
Colon cancer ranks third highest in the number of all cancer cases reported worldwide (1) . According to the statistics of cancer treatment centers of America, the 5-year DFS for Stage IIIA, B and C colon cancers is~89%, 69% and 53%, respectively (2) . Stage IIIA colon cancer patients in general have a better prognosis of all stages mostly due to advances in diagnosis, operative methods and combined chemotherapy. Whereas the disappointing prognosis of Stage IIIC cancers might be caused by increases in micro-metastasis, in clinical practice, individual prognosis of Stage IIIB colon cancer patients is still highly variable in fashion reflective of the fact that knowledge of the metastatic process of Stage IIIB colon cancer is still very limited. Thus, finding disease markers that would allow the identification of individuals who are likely to have worse disease progression is highly desirable as it would allow treatment to be tailored to the individuals most likely to require more aggressive and better targeted therapies. Because miRNAs can control many aspects of cell growth and function, analysis of their expression would appear to offer ways to gain better understanding of cancer onset and progression and some should work as markers of disease status. Here, we propose that miRNA expression patterns of tumor cells could serve as novel molecular biomarkers to predict the prognosis of Stage IIIB colon cancers that so far have no readily identifiable markers useful in diagnosis.
For their expression, miRNAs are first transcribed by RNA polymerase II and processed to form hairpin-like intermediates called pre-miRNAs, which are~70-100 nucleotides long and have two nucleotide overhangs at their 3' ends (3, 4) . Exportin-5 then transports these pre-miRNAs out of the nucleus and into the cytoplasm for further processing, converting the pre-miRNA into conserved, endogenous, small noncoding mature RNAs (5). It is these mature miRNAs of 18-25 nucleotides in length that can control cellular function through recognition of specific targets by complementary base pairing, forming either RNA-induced silencing complexes (RISC), inducing mRNA degradation or inhibiting mRNA translation (6) . miRNAs have been shown to regulate the activity of nearly 30% of all protein-coding genes (7). Importantly, a significant number of miRNAs targeted domains are located at unstable regions or genomic regions linked to cancer (8) . Because of their capability to regulate almost all aspects of cellular function, such as differentiation, development, apoptosis, proliferation and increasing sensitivity or resistance to chemotherapy (9) , miRNAs are now receiving increased attention to understand their roles in cancer etiology and progression. With regard to cancer, increasing evidence has shown miRNA can function as a novel class of oncogene suppressor, and correlations between differential miRNA expression and colon cancer have been discovered. As examples, miRNA-143-3p, miRNA-212, miRNA-151 and miRNA-144 were shown to reflect the microsatellite status of colon cancer (10) and high miRNA-21 expression was shown to be associated with poor survival in studies of colon carcinoma (11) (12) (13) .
To date, no study has focused on the classification of miRNAs for Stage IIIB colon cancers. Due to the technical and bioinformatical challenges, and the high cost per run, only a few publications have employed deep sequencing technology in colon cancer-miRNA studies (14, 15) . Therefore, the aim of the present study was to typify by microarray and qRT-PCR, the differential expression of miRNAs between Stage IIIB colon cancer patients with different pathogenesis looking for miRNA markers that might be predictive of the biological behavior of this stage of colon cancer. We report that miRNA-192-5p is differentially expressed in patients with worse prognosis and that this miRNA could have use in diagnostic, prognostic and therapeutic applications.
Methods

Patients and colon cancer tissue samples
This study was approved by the Sun Yat-sen University cancer center ethical committee, and informed written consent was obtained for all patients investigated. Tissue samples were available from 114 histologically confirmed Stage IIIB colon cancer patients from the Sun Yat-sen University cancer center including frozen tumor tissues from patients that had received curative surgical resection followed by adjuvant mFOLFOX6/XELOX chemotherapy from June 2006 to June 2010. For miRNA microarray analysis, 16 Stage IIIB patients were selected and separated into case (eight patients: four right colon cancer patients, four left colon cancer patients) and control (eight patients: four right colon cancer patients, four left colon cancer patients) groups (only T3-4a-N1a-1b-M0 phenotype). All patients organized into the case group had liver metastasis between 8 months and 18 months after radical operation to remove their colon cancers. In contrast, patients in the control group were considered cured and were without any sign of metastasis or cancer recurrence after at least 5 years follow-up period. Exclusion criteria for all patients were age <18 years and older than 85 years, severe complications, multi-primary cancer, family history (first-degree and second-degree relatives with any kind of cancer), familial adenomatous polyposis, incomplete chemotherapy. Strict inclusion criteria for the case and control group were age between 30 years and 60 years, G2 pathological grade, serum carcinoembryonic antigen (CEA) ≤5ng/ml. All patients in the case group died due to colon cancer, and all patients in the control group were living healthily until the following-up date. Tumor recurrence was scored by physical examination, CEA assay, abdominal and thoracic imaging monitored every 3-6 months for the first 3 years, then every 6 months for the following 2 years, ultimately with only an annual check up after 5 years.
For the remaining 98 Stage IIIB colon cancer patients (41 right colon cancer patients, 57 left colon cancer patients) (including T3-4aN1a-bM0, T2-3N2aM0 and T1-2N2bM0 phenotypes), qRT-PCR analysis was performed on frozen tumor tissues looking at the expression patterns of the targeted miRNAs. Fresh samples from colon cancer tissue were obtained and immediately snap frozen in liquid nitrogen and stored at -80°C until RNA extraction. In this group of patients, 21 cases had liver metastases, four cases had lung metastases, two cases had bone metastases, one case had brain metastases, four cases had mult-metastases.
miRNA microarray and data analysis
Total RNA was extracted from tumor tissues using the Trizol reagent (Invitrogen) and miRNA isolated using the mirVana miRNA Isolation Kit (Ambion, Austin, USA) according to manufacturer protocols. The purity and concentration of RNA were determined from OD260/280 spectrophotometery (NanoDrop ND-1000). RNA integrity was determined by capillary electrophoresis using the RNA 6000 Nano Lab-on-a-chip Kit and the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, USA). Only RNA extracts with miRNA192-5p for colon cancer RNA integrity number values >6 were used for further analysis. Profiling of miRNA contained in tumor tissue was performed using an Agilent miRNA array which contained 1887 human mature and 121 human virus related miRNAs. All miRNA array data were analyzed using GeneSpring software V12 (Agilent) and Log2 transformed by CLUSTER3.0 software. Tree visualization was also performed using Java Treeview software (Stanford University School of Medicine, Stanford, USA).
Quantitative RT-PCR and data analysis
Quantitative RT-PCR was performed to validate miRNA expression levels. For this analysis, RNA was purified from colon cancer tissue. Total RNA was first extracted using RNeasy columns (Qiagen) according to manufacturer instructions. Total RNA was then reverse-transcribed into cDNA (Clontech Kit). Finally, a SYBR green real-time PCR kit was used for the quantification of gene expression levels. Gene expression was measured in triplicate and data were processed using the 2 -△△ CT method and normalization to control. A two-sided P value <0.05 was considered statistically significant for data measurements.
Results
The Table 2 . Tissue samples used for quantification of miRNA levels were derived from patients with the median age at diagnosis of 52 years of age (range 28-73 years) with an average 5-year DFS and OS of 67.3% and 69.4%, respectively.
miRNA profiling
Microarray analysis was performed on case and control group Stage IIIB colon cancer samples that included 1887 human mature and 121 human virus related miRNAs in the screening. We found the differential expression of miRNA-192-3p and miRNA-192-5p of most interest as these two miRNA species were down expressed in all the case group patients compared with the control (P = 0.026 and 0.042, respectively). The active sequences of miRNA-192-3p and for miRNA-192-5p are CTGTGACCTATGGAATTGG and GGCTGTCAATTCATAGGTC, respectively. Bootstrap clustering analysis and log-log scatter plot are shown in Fig. 1 .
Expression of miRNA-192-3p and miRNA-192-5p
In the 98 colon cancer samples analyzed by qRT-PCR, we found the mean expression of miRNA-192-3p was 1.01 (ranged 0.02-2.30). Sixty eight cases (69.4%) had low miNRA-192-3p expression (<1.01) whereas 30 cases (30.6%) had high expression (>1.01). The mean expression of miRNA-192-5p in all patients was 98.05 (ranged 0.01-772.47). Sixty cases (61.2%) had low miRNA-192-5p expression (<98.05) and 38 cases (38.8%) had high miRNA-192-5p expression (>98.05). The expression of miRNA-192-3p showed no impact on the expression of miRNA-192-5p (95% CI 0.643-0.662, P = 0.65). The miRNA-192-3p and miRNA-192-5p expression data for the 98 Stage IIIB colon cancer patient samples with clinicopathological parameters are shown in Table 2 .
Relationship between miRNA-192-3p and miRNA-192-5p expression and survival
The most striking result of our analysis was the finding that the 5-year DFS was significantly higher in the miRNA-192-5p higher expression group (84.21%) than in the group with lower miRNA-192-5p expression (38.8%, HR: 3.74, 95% CI: 1.52-9.23, P = 0.042). In addition, the OS was also found to be higher for the miRNA-192-5p group with greater expression (89.47%) than in the miRNA-192- Multivariate analyses of survival Age, gender, CEA level, sub-stage, pathology and miRNA-192-5p showed statistically significant differences between case versus cured Stage IIIB colon cancer patients in univariate Cox analysis (P < 0.05) as shown in Table 3 . All parameters were dichotomy variables. Among the variables analyzed in the multivariate Cox model, age (HR 0.59, 95%CI: 0.42-0.77, P < 0.001), CEA level (HR 0.31, 95%CI: 0.14-0.48, P < 0.001), stage (T3-4aN1a-bM0/T2-3N2aM0 vs T1-2N2bM0, HR 0.99, 95%CI: 0.08-1.89, P = 0.032) and pathology (G1/2 vs 3, HR 1.37, 95%CI: 1.14-1.61, P = 0.024) were significantly associated with DFS. Age (HR 0.48, 95%CI: 0.36-0.61, P < 0.001), CEA level (HR 0.39, 95%CI: 0.28-0.52, P < 0.001), stage (T3-4aN1a-bM0/T2-3N2aM0 vs T1-2N2bM0, HR 1.13, 95%CI: 0.22-2.05, P = 0.022) and pathology (G1/2 vs 3, HR 1.34, 95%CI: 1.18-1.49, P = 0.034) also had a statistically significant relationship to OS. From this multivariate analysis, miRNA-192-5p expression remained an independent significance factor for DFS and OS in Stage IIIB colon cancer patients (DFS HR 0.59, 95%CI: 0.42-0.77, P = 0.023; OS HR 0.50, 95%CI: 0.39-0.61, P = 0.024).
Discussion
In the present study, deep sequencing was performed to characterize the miRNA transcriptome of Stage IIIB colon cancers, using tumor samples from a select restricted case versus control group patients each with a recorded long-term follow-up of monitoring disease progression. Most interesting from this analysis, we found that miRNA192-5p was significantly lower expressed in the patient group that suffered relapse and progressive disease versus cured controls suggesting that lower miRNA192-5p levels might associate with poorer prognosis for Stage IIIB colon cancer patients. This lower level of expression for miRNA-192-5p we found also appeared to be associated from our qRT-PCR expression analysis of the 98 Stage IIIB colon cancer patient tumor samples to be predictive of survival as well. Our results suggest that monitoring of miRNA192-5p levels could be useful for monitoring Stage IIIB colon cancer disease in clinical practice.
MiRNA-192 was first sequenced by Lagos-Quintana et al. in 2003 (16) . The miRNA-192 gene is located on human chromosome 11 and is transcribed as a cluster along with miRNA-194. While miRNA-192 has been reported to be up-regulated in multiple cancer types including esophageal squamous cell carcinoma (ESCC) (17) , gastric cancer (18) , hepatocellular carcinoma (HCC) (19, 20) , neuroblastoma (NB) (21) and pancreatic ductal adenocarcinoma (22) , there are also reports demonstrating its diminished expression Figure 1 . Bootstrap clustering analysis and log-log scatter plot. Picture A: Bootstrap clustering analysis on tumor samples from case and control groups. Each column represents a single miRNA, and each row represents a sample. Number 2, 3, 4, 5, 6, 8, 9 and 10 belong to the case group. Number 11, 12, 13, 15, 16, 17, 19 and 20 belong to the control group. Yellow colors on the heat map indicate expression levels higher than the median, while blue colors show expression levels lower than the median. Picture B: Log-Log scatter plot for miRNA. miRNA192-5p for colon cancer in other cancers. Expression of miRNA-192 has been found to be down-regulated in colorectal cancer (23) (24) (25) , breast cancer (26) and renal cell cancer (RCC) (27) . In our study, the expression of miRNA-192-5p is greatly diminished for case group patients that suffered relapse and progressive Stage IIIB colon cancers that ultimately led to patient death, that raises questions to its possible role(s) in disease. In our study, we selected Stage T3-4a N1a-1b M0 colon cancer patients for microarray screening and focused on Stage IIIB patients for survival analysis. Yet, in our statistical analysis substages of disease still were found to have a close association with expression levels of miRNA-192-5p, and supports the differential expression of miRNA-192-5p is present in various stages of colon cancer. Overall, our findings suggest that loss of function of miRNA-192 through its down regulation play a significant role in tumor progression and it may act as a tumor suppressor in colon cancer. Furthermore, all patients received adjuvant mFOLFOX6/ XELOX chemotherapy from June 2006 to June 2010, this suggested that miRNA-192-5p might play also a projective function for adjuvant chemotherapy in colon cancers. However, there are some limitations to the current study. One is that it was limited to the examination of Stage IIIB colon cancer and confirmation of reductions in miRNA-192-5p for other stage colon and rectal cancers would clearly provide additional support for the importance of miRNA-192-5p in tumor pathogenesis, which need further study to explore the expression of miRNA-192-5p in Stage IIIA and IIIC colon cancers and rectal cancers. Second, we only focused on finding the relationship of miRNA-192-5p expression with survival time. It will be very important to identify the relevant mechanisms and pathways of action that can account for the role(s) of miRNA-192-5p in colon cancer.
Conclusion
We have used a restricted set of patients with demonstrated differential disease progression to investigate whether the expression of miRNA can affect the development of disease in Stage IIIB colon cancers. From our results, we found that miRNA-192-5p could serves as a potential diagnostic and/or therapeutic target in colon cancer. We envision that the testing of Stage IIIB colon cancer patients for miRNA-192-5p levels will greatly add to the prognostic capacity of doctors to help direct patient therapy.
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